Which statement about Carvedilol is true regarding its mechanism of action?

The statement that Carvedilol is a selective α1 and nonselective β-adrenergic blocker accurately describes its mechanism of action. Carvedilol functions by blocking both alpha-1 and beta-adrenergic receptors, which helps in lowering blood pressure and heart rate. By inhibiting beta-adrenergic receptors, it reduces the effects of adrenaline in the heart, leading to decreased heart rate and myocardial contractility. The blockade of alpha-1 receptors contributes to vasodilation, further enhancing its antihypertensive effects. This dual action is particularly beneficial in treating conditions like hypertension and heart failure, as it addresses multiple pathways involved in cardiovascular regulation.

In contrast, other statements do not align with the pharmacological profile of Carvedilol. For instance, it does not increase heart rate; if anything, its beta-blocking effects typically lead to a reduction in heart rate. It is also not an ACE inhibitor—those are a different class of medications aimed at blocking the angiotensin-converting enzyme, which is not related to Carvedilol's mechanism. Furthermore, stating that it acts only on beta-adrenergic receptors is misleading, as the multi-receptor blockade is crucial to its overall effects.